The findings suggested that SDF-1 could be a potential therapeutic target in acute stroke patients with diabetes mellitus in future studies and the use of SDF-1 inhibitors in medical treatment shows promise as a potential therapeutic intervention for secondary prevention following an ischemic stroke with diabetes mellitus. Here, CXCL12 is linked to diabetes mellitus.